CSF NfL levels were found to be significantly elevated in the preclinical AD group compared to the normal AD biomarkers group (p < 0.001; area under the ROC curve [AUC] = 0.79, CI 0.60–0.98, p = 0.011). Here, NEFL is linked to Alzheimer disease.